NRM-823

Phase 1Small molecule

NNormunity AccelCo, Inc.

NRM-823 is one of 15 small molecule programs targeting HNSCC. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HNSCCRecruiting

HNSCCPhase 1

Recruiting

Competition

Competitive Landscape

19 competitors in HNSCC

#DrugCompanyPhaseTrials

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

3 2

Opdivo

Bristol-Myers Squibb

Phase 1

2 3

Vectibix

Amgen

Phase 1

1 4

Methylthioninium Chloride

PProvepharm SAS

Phase 1

1 5

SG001

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2

1 6

Keytruda

Merck & Co.

Preclinical

2 7

Beyfortus

BeiGene

Preclinical

1 8

JMT101

CCSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 2

1 9

SYS6002

CCSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 2

1 10

Gilotrif

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

HNSCC

NCT07182149

Clinical

Trials by Indication[1]

HNSCC1 trial

A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination With Immune Checkpoint Inhibition in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Recruiting·NNormunity AccelCo, Inc.·Phase 1·NCT07182149·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NRM-823. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NRM-823 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NRM-823. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Normunity AccelCo, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNormunity AccelCo, Inc.

NRM-823

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

HNSCC1 trial

References

Drug Info

Quick Facts

Related News